On p. 208 of the March 2002 issue, the Business and Regulatory News Analysis story “Troubled big pharma turns away from biotech” contains an editing error. The text, “Patent expirations are one reason; BMS's Taxol, Eli Lilly's (Indianapolis, IN) Prozac, Merck's Mevacor and Pfizer's Accupril all recently went off-patent. These were soon followed by, among other blockbusters, Schering Plough's Claritin and Merck's Prinivil,” should have read, “Patent expirations are one reason; BMS's Taxol, Eli Lilly's (Indianapolis, IN) Prozac, Merck's Mevacor and Pfizer's Accupril all recently went off-patent. They are soon to be followed by Schering-Plough's Claritin and Merck's Prinivil, among other blockbusters.” Claritin and Prinivil are not yet off-patent. Nature Biotechnology apologizes for the error.
Additional information
The online version of the original article can be found at 10.1038/nbt0302-207b
Rights and permissions
About this article
Cite this article
Erratum: “Troubled big pharma turns away from biotech”. Nat Biotechnol 20, 338 (2002). https://doi.org/10.1038/nbt0402-338b
Issue Date:
DOI: https://doi.org/10.1038/nbt0402-338b